26th Jul 2024 13:27
AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Says it is "committed to working closely" with the US Food & Drug Administration to bring an Imfinzi-based treatment to patients with resectable non-small cell lung cancer, following a review of a phase III trial by the Oncologic Drugs Advisory Committee, an advisory body for the FDA. Astra says the Aegean trial of Imfinzi, whose generic name is durvalumab, showed a "statistically significant and clinically meaningful 32% reduction in the risk of recurrence, progression events or death versus chemotherapy alone". Read More
